Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Newmont Corporation (NEM) Price & Performance

Amylx Pharmaceuticals IncTrade
Newmont CorporationTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Newmont Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $23.91 (market cap $2.64B), while Newmont Corporation trades at $119.39 (market cap $123.50B). The key difference: Newmont Corporation is far larger — about 46.8× Amylx Pharmaceuticals Inc's market cap, and Newmont Corporation pays a 0.89% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMLXNEM
Market Cap
$2.64B$123.50B
Sector
HealthBasic Materials
52-Week High
$24.19$131.95
52-Week Low
$7.82$67.38
Enterprise Value
$2.39B$120.09B
Dividend Yield
0.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.

Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.

Newmont Corporation

Newmont Corporation (NEM) trades at $117.26, up 3.79% over 24 hours, near its 52-week high. The stock exhibits strong bullish technical signals and robust fundamentals, with revenue growing to $22.67 billion in 2025 and net income reaching $7.09 billion. Recent news highlights the resolution of a Nevada joint venture dispute with Barrick Mining, providing operational clarity.

The outlook for NEM remains positive, supported by strong earnings beats, a favorable analyst consensus, and rising gold prices. Key risks include gold price volatility and execution of production targets. The consensus price target of $133.00 suggests upside potential from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Newmont Corporation

Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.

Read more on NEM